Journal Mobile Options
Table of Contents
Vol. 112, No. 4, 2004
Issue release date: November 2004

Primary Salivary Gland Lymphoma: A Clinicopathologic Study of 23 Cases in Taiwan

Dunn P. · Kuo T.-t. · Shih L.-Y. · Lin T.-L. · Wang P.-N. · Kuo M.-C. · Tang C.-C.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Twenty-three patients with primary salivary gland lymphoma were diagnosed between 1990 and 2001. The sites of involvement were the parotid gland in 13, the submandibular gland in 9 and the minor salivary gland in 1. The sites of lymphoma involvement beyond the salivary glands were the cervical lymph nodes in 7, bone marrow in 3, the axillary lymph nodes in 3, the nasopharynx in 2, the abdominal lymph nodes in 2, the palate, the subconjunctiva, and the spleen in 1 each patient. Histologically, 19 patients had lymphomas of mucosa-associated lymphoid tissue (MALT) with myoepithelial sialadenitis in 13, 3 patients had diffuse large cell lymphomas and 1 had follicular lymphoma. Six patients were in stage I, 4 in II, 1 in III and 12 in IV. Eight of 23 patients (35%) had autoimmune diseases before or after the diagnosis of NHL and all suffered from MALT lymphoma. Four patients with parotid MALT lymphoma had primary or secondary Sjögren’s syndrome. One each patient suffered from hyperthyroidism, systemic lupus erythematosus, membranoproliferative glomerulonephritis and cryoglobulinemia, respectively. All the 6 stage I patients had achieved complete remission (CR) without relapses 17–84 months (median 44 months) after treatment. Excluding a stage IV patient with follicular lymphoma who died at 3.5 months without treatment, CR was achieved in all of the remaining 16 patients. However, a high relapse rate (9/16, 56%) was noted in stage II–IV patients. These patients tended to relapse in the original sites, but achieved CR again after chemotherapy or radiotherapy. One patient with MALT lymphoma developed histologic transformation into diffuse large lymphoma during relapse and died of refractory disease. Overall, only 2 patients succumbed. The overall survival and relapse-free survival rates at 5 years were 94.7 and 51.4%, respectively. Thus, salivary gland lymphoma proved to be an indolent disease.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Gleeson MJ, Bennett MH, Cawson RA: Lymphomas of salivary glands. Cancer 1986;58:699–704.
  2. Schusterman MA, Granick MS, Erickson ER, Newton D, Hanna DC, Bragdon RW: Lymphoma presenting as a salivary gland mass. Head Neck Surg 1988;10:411–415.
  3. Freeman G, Berg JW, Culter SJ: Occurrence and prognosis of extranodal lymphomas. Cancer 1972;29:252–260.
  4. Hyman GA, Wolff M: Malignant lymphomas of the salivary glands. Review of the literature and report of 33 new cases, including four cases associated with the lymphoepithelial lesion. Am J Clin Pathol 1976;65:421–438.
  5. Takahashi H, Tsuda N, Tezuka F, Fujita S, Okabe H: Non-Hodgkin’s lymphoma of the major salivary gland: A morphologic and immunohistochemical study of 15 cases. J Oral Pathol Med 1990;19:306–312.
  6. Wolvius EB, van der Valk P, van der Wal JE, van Diest PJ, Huijgens PC, van der Waal I, Snow GB: Primary non-Hodgkin’s lymphoma of the salivary glands. An analysis of 22 cases. J Oral Pathol Med 1996;25:177–181.
  7. Harris NL: Lymphoid proliferations of the salivary glands. Am J Clin Pathol 1999;111(suppl 1):S94–S108.
  8. Mehle ME, Kraus DH, Wood BG, Tubbs R, Tucker HM, Lavertu P: Lymphoma of the parotid gland. Laryngoscope 1993;103:17–21.
  9. Sarris AH, Papadimitrakopoulou V, Dimopoulos MA, Smith T, Pugh W, Ha GS, McLaughlin P, Callender D, Cox J, Cabanillas F: Primary parotid lymphoma: the effect of International Prognostic Index on outcome. Leuk Lymphoma 1997;26:49–56.
  10. Barnes L, Myers EN, Prokopakis EP: Primary malignant lymphoma of the parotid gland. Arch Otolaryngol Head Neck Surg 1998;124:573–577.
  11. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994;84:1361–1392.
  12. Jaffe ES, Harris NL, Stein H, Vardima JW: World Health Organization Classification of Tumors: Tumors of Haematopoietic and Lymphoid Tissues. Lyon, IARC Press, 2001.
  13. Kassan SS, Thomas TL, Moutsopoulos HM, Hoover R, Kimberly RP, Budman DR, Costa J, Decker JL, Chused TM: Increased risk of lymphoma in Sicca syndrome. Ann Intern Med 1978;89:888–892.
  14. Hyjek E, Smith WJ, Isaacson PG: Primary B-cell lymphoma of salivary glands and its relationship to myoepithelial sialadenitis. Hum Pathol 1988;19:766–776.
  15. McCurley TL, Collins RD, Ball E, Collins RD: Nodal and extranodal lymphoproliferative disorders in Sjögren’s syndrome: A clinical and immunopathologic study. Hum Pathol 1990;21:482–492.
  16. Zufferey P, Meyer OC, Grossin M, Kahn MF: Primary Sjögren’s syndrome (SS) and malignant lymphoma. A retrospective cohort study of 55 patients with SS. Scand J Rheumatol 1995;24:342–345.
  17. Royer B, Cazals-Hatem D, Sibilia J, Agbalika F, Cayuela JM, Soussi T, Maloisel F, Clauvel JP, Brouet JC, Mariette X: Lymphomas in patients with Sjögren’s sydrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. Blood 1997;90:766–775.
  18. Biasi D, Caramaschi P, Ambrosetti A, Carletto A, Mocella S, Randon M, Bambara LM: Mucosa-associated lymphoid tissue lymphoma of the salivary glands occurring in patients affected by Sjögren’s syndrome: Report of 6 cases. Acta Haematol 2001;105:83–88.
  19. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M: Report of the Committee on Hodgkin’s Disease Staging Classification. Cancer Res 1971:31:1860–1861.
  20. Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri G, Bencivelli W, Bernstein RM, Bjerrum K, Braga S, Coll J, De Vita S, Drosos AA, Ehrenfeld M, Hatron PY, Hay EM, Isenberg DA, Janin A, Kalden JR, Kater L, Konttinen YT, Maddison PJ, Maini RN, Manthorpe R, Meyer O, Ostuni P, Pennec Y, Prause JU, Richards A, Sauvezie B, Schiodt M, Sciuto M, Scully C, Shoenfeld Y, Skopouli FN, Smolen JS, Snaith ML, Tishler M, Todesco S, Valesini G, Venables PJW, Wattiaux MJ, Youinou P: Preliminary criteria for the classification of Sjögren’s syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum 1993;36:340–347.
  21. Isaacson PG: Mucosa-associated lymphoid tissue lymphoma. Semin Hematol 1999;36:139–147.
  22. Zucca E, Conconi A, Pedrinis E, Cortelazzo S, Motta T, Gospodarowicz MK, Patterson BJ, Ferreri AJM, Ponzoni M, Devizzi L, Giardini R, Pinotti G, Capella C, Zinzani PL, Pileri S, López-Guillermo A, Campo E, Ambrosetti A, Baldini L, Cavalli F: Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood 2003;101:2489–2495.
  23. Xu Y, Wiernik PH: Systemic lupus erythematosus and B-cell hematologic neoplasm. Lupus 2001;10:841–850.
  24. Berliner S, Sidi Y, Mor C, Galili N, Weinberger A, Pinkhas J: Systemic lupus erythematosus six years following chemotherapy for malignant lymphoma. Scand J Rheumat 1985;14:276–278.
  25. Moulin B, Ronco PM, Mougenot B, François A, Fillastre J-P, Mignon F: Glomerulonephritis in chronic lymphocytic leukemia and related B-cell lymphomas. Kidney Int 1992;42:127–135.
  26. Ferri C, Caracciolo F, Zignego AL, Civita LL, Monti M, Longombardo G, Lombardini F, Greco F, Capochiani E, Mazzoni A, Mazzaro C, Pasero G: Hepatitis C virus infection in patients with non-Hodgkin’s lymphoma. Br J Haematol 1994;88:392–394.
  27. Luppi M, Ferrari MG, Bonaccorsi G, Longo G, Narni F, Barozzi P, Marasca R, Mussini C, Torelli G: Hepatitis C virus infection in subsets of neoplastic lymphoproliferations not associated with cryoglobulinemia. Leukemia 1996;10:351–355.
  28. Zuckerman E, Zuckerman T, Levine AM, Douer D, Gutekunst K, Mizokami M, Qian DG, Velankar M, Nathwani BN, Fong T-L: Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma. Ann Intern Med 1997;127:423–428.
  29. Mele A, Pulsoni A, Bianco E, Musto P, Szklo A, Sanpaolo MG, Iannitto E, de Renzo AD, Martino B, Liso V, Andrizzi C, Pusterla S, Dore F, Maresca M, Rapicetta M, Marcucci F, Mandelli F, Franceschi S: Hepatits C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. Blood 2003;102:996–999.
  30. Collier JD, Zanke B, Moore M, Kessler G, Krajden M, Shepherd F, Heathcote J: No association between hepatitis C and B-cell lymphoma. Hepatology 1999;29;1259–1261.
  31. Germanidis G, Haioun C, Pourquier J, Gaulard P, Pawlotsky J-M, Dhumeaux D, Reyes F: Hepatitis C virus infection in patients with overt B-cell non-Hodgkin’s lymphoma in a French center (letter). Blood 1999:73:1778–1779.

    External Resources

  32. Luppi M, Longo G, Ferrari MG, Ferrara L, Marasca R, Barozzi P, Morselli M, Emilia G, Torelli G: Additional neoplasms and HCV infection in low-grade lymphoma of MALT type. Br J Haematol 1996;94:373–375.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50